Other
Staphylococcus Aureus Infection
16
Pipeline Programs↗
0
Active Trials↗
10
Companies Involved↗
Staphylococcus aureus infection is an emerging landscape with 16 programs across 10 companies. The most active players are Hyundai Pharmaceutical Co., LTD., Roche, Hikma Pharmaceuticals LLC. 10 therapies are approved with 1 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 1
No programs
Phase 31
Analysis
Trial Status
4
clinical trials
Completed2 · 50%
Terminated1 · 25%
Withdrawn1 · 25%
Clinical Trials
Trial Activity
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)